🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Spain
Clinical trial register · European Union · CTIS

Clinical Trials in Spain

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12467 total CTIS records — a stated recency window, not the full historical archive. Synced 22 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,467
Total on CTIS
full historical archive
744
Phase III
within the shown window
Top member states
Spain 1018 France 887 Germany 856 Italy 735 Poland 580 Netherlands 527
Narrow the registerReset
Phase
Phase I 557 Phase I/II 211 Phase II 727 Phase III 744 Phase IV 261
Lead sponsor
AstraZeneca AB 62 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 47 Pfizer Inc. 44 Novo Nordisk A/S 43
Member state
Spain 1018 France 887 Germany 856 Italy 735 Poland 580 Netherlands 527 Belgium 424 Czechia 329
All 28 states
1018 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I
A Phase 1 Trial of GEN1119 in Participants with Solid Tumors
2026-525610-62-00Solid Tumors
Genmab A/S
Neoplasms
Spain, France
10/08/2026
Phase III
A single-arm, multicenter, phase III study to assess efficacy, pharmacokinetics, safety and tolerability of atrasentan in pediatric patients of 2 to <18 years of age with primary immunoglobulin A nephropathy (IgAN)
2025-522824-29-00Primary IgAN
Novartis Pharma AG
Immune system processes
France, Spain
10/08/2026
Phase III
Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity
2025-524626-18-00Overweight and obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Netherlands, Belgium, Greece, Poland, Spain, Denmark, France, Bulgaria, Sweden
10/08/2026
Phase III
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs
2025-523333-26-00Graves' Disease (GD)
Argenx
Hormonal diseases
Italy, Czechia, Spain, Denmark, Belgium, Romania, Latvia, France, Germany, Greece, Sweden, Poland, Lithuania, Bulgaria
07/08/2026
Phase IV
HORUS-Cytomegalovirus Open Proof-of-concept Exploratory trial
2025-524845-28-00Cytomegalovirus infection in solid-organ transplant recipie…
Centre Hospitalier Universitaire Vaudois
Virus Diseases
France, Spain
07/08/2026
Phase IV
A Phase 4, Pragmatic, Randomized Trial to Evaluate the Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years (DAN-COMBO)
2026-526720-49-00SARS-CoV-2 infection, Influenza infection
Gentofte Hospital, Moderna Inc.
Virus Diseases
Denmark, Spain
07/08/2026
Phase IV
CLINIC-CURE, a pilot exploratory clinical trial of analytical treatment interruption in people with HIV with a highly favorable profile
2026-526395-23-00HIV
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Virus Diseases
Spain
06/08/2026
Phase IV
Influence of Doxycycline Use as Prophylaxis for Sexually Transmitted Infections on Bacterial Resistance and Gut Microbiota: MiDoxyR-PEP Study
2025-525150-19-01Colonization by methicillin-resistant S. aureus and gut mic…
Instituto De Investigacion Marques De Valdecilla
Bacterial Infections and Mycoses
Spain
06/08/2026
Phase I/II
Trial to study the safety, pharmacokinetics and preliminary antitumour activity of ODM-216 in patients with cancer
2026-525864-17-00Advanced solid tumours
Orion Corporation
Neoplasms
Spain
06/08/2026
Phase III
A Phase 3, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting or Cabotegravir Long-acting Plus Rilpivirine Long-acting in Adults and Adolescents with HIV who are Virologically Suppressed on ART
2024-518511-19-00HIV Infections
Viiv Healthcare UK Limited
Immune System Diseases
Spain
05/08/2026
Phase II
A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)
2025-525016-41-00Idiopathic Pulmonary Fibrosis
AstraZeneca AB
Respiratory Tract Diseases
Poland, Hungary, Netherlands, Germany, Spain, Greece, Bulgaria, Italy, France, Denmark
04/08/2026
Phase I
Study in healthy volunteers to evaluate how the body processes Iadademstat and if food affects it
2026-525953-35-00Healthy Volunteers
Oryzon Genomics S.A.
Not possible to specify
Spain
04/08/2026
Phase I
A study of enzomenib investigating potential drug-drug interactions and the effect of liver impairment in adult patients with advanced cancer
2025-524652-63-00Advanced Cancer
Sumitomo Pharma America Inc.
Neoplasms
Spain, Bulgaria, Poland, Romania
04/08/2026
Phase III
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron compared with Placebo in Adults with Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)
2025-523940-12-00type 2 diabetes mellitus
AstraZeneca AB
Nutritional and Metabolic Diseases
Germany, Bulgaria, Spain, Denmark
03/08/2026
Phase III
A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination with Venetoclax and Azacitidine in Adult Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy
2025-523724-47-00Acute Myeloid Leukemia
AbbVie Deutschland GmbH & Co. KG
Neoplasms
France, Austria, Spain
03/08/2026
Phase III
A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)
2025-523884-39-00Systemic sclerosis
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Skin and Connective Tissue Diseases
Denmark, Hungary, Sweden, Netherlands, Germany, Belgium, France, Greece, Norway, Finland, Czechia, Portugal, Bulgaria, Spain, Austria, Romania, Croatia, Poland, Estonia, Italy, Lithuania
03/08/2026
Phase I
Feasibility clinical trial of the sequential combination of AloCelyvir and activated tumor-infiltrating lymphocytes (TILs) for the treatment of children and young adults with advanced neuroblastoma
2025-522006-21-00High-risk relapsed/refractory (R/R) neuroblastoma (NB).
Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa
Neoplasms
Spain
03/08/2026
Phase III
A Phase 3, Randomized, Double-blind, and Active‑controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ‑78934804 in Participants With Moderately to Severely Active Crohn’s Disease
2026-525922-39-00Moderately to Severely Active Crohn’s Disease
Janssen Cilag International
Immune System Diseases
Norway, Romania, Austria, Italy, Slovakia, Germany, Hungary, Netherlands, Belgium, France, Portugal, Czechia, Poland, Spain, Greece
03/08/2026
Phase III
A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis
2026-525923-26-00Moderately to Severely Active Ulcerative Colitis
Janssen Cilag International
Immune System Diseases
France, Bulgaria, Romania, Slovakia, Norway, Denmark, Greece, Italy, Austria, Poland, Netherlands, Czechia, Germany, Belgium, Spain, Hungary, Portugal
03/08/2026
Phase I
A study to test how well different doses of BI 3822971 are tolerated by people with advanced cancer (solid tumours)
2026-525785-22-00solid tumours
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Spain
31/07/2026
Phase I/II
A Phase 1b/2a first-in-human, multicentre, randomized, double-blind, placebo-controlled study of multiple ascending dose (Part1) followed by an open-label extension (Part2) to assess the safety, tolerability, and pharmacokinetics of intrathecally administered S233107 in participants with spinocerebellar ataxia type 3
2025-525111-17-00Spinocerebellar ataxia type 3
Institut De Recherches Internationales Servier IRIS
Nervous System Diseases
France, Denmark, Spain, Portugal
30/07/2026
Phase III
J3L-MC-EZEJ: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event
2025-524858-34-00Lipoprotein(a), Atherosclerosis, Cardiovascular Diseases
Eli Lilly & Co.
Cardiovascular Diseases
Hungary, Czechia, Spain, Netherlands
30/07/2026
Phase I
A Phase 1a/1b, multicenter, open-label study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PLN-101095 alone and in combination with pembrolizumab in adults with advanced or metastatic solid tumors following progression on immune checkpoint inhibitor therapy
2026-526116-36-00Advanced or metastatic solid tumours
Pliant Therapeutics Inc.
Neoplasms
Spain
29/07/2026
Phase I/II
A Phase I/II, randomized, placebo-controlled, multi-arm, dose-finding study to evaluate the safety, efficacy and immunogenicity of an Acne mRNA vaccine candidate in adults with moderate to severe acne 18 to 45 years of age
2025-521740-38-00Acne
Sanofi Pasteur Inc.
Skin and Connective Tissue Diseases
Spain, Germany, Poland
29/07/2026
Phase III
A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)
2026-526304-79-00Heart failure with preserved ejection fraction (HFpEF) and …
AstraZeneca AB
Cardiovascular Diseases
Spain, Hungary, Germany, Poland, Italy, Bulgaria, Netherlands, Austria, Romania, Sweden, France, Greece, Slovakia, Czechia
29/07/2026
Phase II
A Phase 2 Study of Alisertib in Combination with Paclitaxel in Patients with Small Cell Lung Cancer
2026-525382-47-00Small Cell Lung Cancer (SCLC)
Puma Biotechnology Inc.
Neoplasms
France, Poland, Spain
28/07/2026
Phase IV
STRategiEs for Antiplatelet Management foLlowIng acute coroNary syndromE (STREAMLINE)
2026-525933-22-00ischemic heart disease
Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz
Cardiovascular Diseases
Spain, Norway
28/07/2026
Phase I
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination with Bevacizumab in Adult Participants with Ovarian Cancer
2025-522209-40-00Ovarian Cancer
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Portugal, Denmark, Spain, France
27/07/2026
Phase I
A Phase 1 Study of PRT12396 in Participants with Select Myeloproliferative Neoplasms
2026-525484-40-00Post-Essential Thrombocythemia Myelofibrosis, Post-Polycyth…
Prelude Therapeutics Inc.
Neoplasms
Italy, France, Spain
27/07/2026
Phase II
A Cancer Research UK Phase II trial of CY-101 given via intratumoural administration in locally advanced or metastatic adrenocortical carcinoma (CLARITY)
2025-522757-19-00LOCALLY ADVANCED OR METASTATIC ADRENOCORTICAL CARCINOMA
Cancer Research UK
Neoplasms
Spain, France, Germany, Norway
27/07/2026
Phase II
A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination with Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer
2025-524816-13-00Non-small Cell Lung Cancer
Janssen Cilag International
Neoplasms
Spain
27/07/2026
Phase III
A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes
2025-522488-14-00Participants with obesity with or without type 2 diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Greece, Portugal, France, Slovakia, Bulgaria, Netherlands, Romania, Italy, Austria, Poland, Hungary, Spain, Czechia, Belgium
27/07/2026
Phase III
A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
2025-523819-11-00Small Cell Lung Cancer
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Italy, Greece, Spain, Belgium, France, Austria, Germany
27/07/2026
Phase III
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold)
2025-524688-19-00Participants Living with Obesity or Overweight with at leas…
AstraZeneca AB
Nutritional and Metabolic Diseases
Spain, Germany, Italy, Poland
27/07/2026
Phase III
An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease
2025-523960-19-00Advanced or Metastatic HR+/HER2- Breast Cancer
BeOne Medicines I GmbH
Neoplasms
Poland, Italy, Germany, France, Spain
27/07/2026
Phase III
An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115) in Participants Aged 15-60 Years With Spinal Muscular Atrophy Who Are Either Treatment-Naïve or Have Previously Been Treated With Risdiplam
2025-524054-34-00Spinal Muscular Atrophy
Biogen Idec Research Limited
Nervous System Diseases
Finland, Spain, Italy, Poland, Ireland, Germany, France
24/07/2026
Phase III
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)
2025-523994-41-00Chronic kidney disease (CKD) in adults, with specified rang…
AstraZeneca AB
Cardiovascular Diseases
Czechia, Italy, Hungary, Romania, Bulgaria, Sweden, Denmark, Poland, Spain, Norway, Finland, Greece, France, Germany
24/07/2026
Phase II
IKF-099/D-FLOT-TNT Total Neoadjuvant Treatment with preoperative FLOT/Durvalumab plus postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma
2026-525185-21-00Gastroesophageal Adenocarcinoma
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Digestive System Diseases
Germany, Spain
23/07/2026
Phase III
A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia
2025-524282-24-00Classic Congenital Adrenal Hyperplasia (CAH)
Neurocrine Biosciences Inc.
Hormonal diseases
Czechia, Germany, Sweden, Portugal, Romania, Bulgaria, Italy, Austria, Spain
23/07/2026
Phase III
Prospective, multicentre, open-label, single arm trial on contraceptive efficacy, safety and tolerability of LPRI-CF113 (Drospirenone 4 mg + 2.8 mg) during 13 cycles.
2026-525727-24-00No medical condition
Chemo Research S.L.
Not possible to specify
Sweden, Czechia, Spain, Hungary, Poland, Finland, Romania
23/07/2026
Phase III
A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants with Huntington’s Disease
2025-522263-14-00Huntington’s Disease
Skyhawk Therapeutics Inc.
Nervous System Diseases
Germany, Spain
23/07/2026
Phase I/II
A Phase 1/2, dose escalation and expansion study of TRI-611, an oral ALK molecular glue degrader in participants with advanced ALK-positive NSCLC
2025-524418-27-00Advanced ALK-positive NSCLC
Triana Biomedicines Inc.
Respiratory Tract Diseases
France, Italy, Germany, Spain
22/07/2026
Phase IV
Real-World Effectiveness of the Adjuvanted RSVPreF3 Vaccine in Adults ≥60 Years: A Pragmatic Randomized Trial (BronquiVal)
2026-526804-59-00Respiratory syncytial virus infection–related respiratory d…
Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana
Respiratory Tract Diseases
Spain
22/07/2026
Phase III
Colchicine for the Reduction of Dependency and Vascular Events after an Acute Intracerebral Hemorrhage (CoVasc-ICH2)
2025-523435-18-00Major cardiovascular events (MACE), spontaneous intracerebr…
Hamilton Health Sciences Corporation, PHRI Population Health Research Institute International
Cardiovascular Diseases
Spain, Belgium
22/07/2026
Phase II
Local and systemic immune modulation by Rilvegostomig (AZD2936) in the treatment of advanced gastric cancer (RILVE Project)
2026-525620-23-00advanced gastric cancer
Vall D Hebron Institute Of Oncology
Digestive System Diseases
Spain
22/07/2026
Phase I
Tarlatamab Before and After Surgery for Recurrent High-Grade Glioma
2025-524359-30-00surgically resectable recurrent high-grade glioma
Vall D Hebron Institute Of Oncology
Neoplasms
Spain
22/07/2026
Phase I/II
A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants with Refractory Rheumatoid Arthritis
2025-520666-22-00Refractory, difficult-to-treat Rheumatoid Arthritis
Bristol-Myers Squibb Services Unlimited Company
Immune System Diseases
Poland, Italy, Spain, Germany
22/07/2026
Phase II
A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled Study, to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered Mivelsiran in Adult Participants with Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)
2025-523390-42-00Early-Stage Down Syndrome-Associated Alzheimer’s Disease (D…
Alnylam Pharmaceuticals Inc.
Nervous System Diseases
Italy, Netherlands, Spain, Germany, Ireland
22/07/2026
Phase I
Phase 1/1b Study of BMS-986463 in Advanced Malignant Tumors
2025-523067-38-01Advanced Malignant Tumors; High-grade Serous Ovarian Carcin…
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Spain, France, Italy
21/07/2026
Phase III
A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis
2026-525242-29-00Primary Sclerosing Cholangitis
Ipsen Bioscience Inc.
Digestive System Diseases
Spain, Sweden, Germany, Romania, Finland, Portugal, Austria, Italy, Denmark, Czechia, France, Netherlands, Poland, Belgium, Norway
21/07/2026
Phase I/II
A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and dose optimization study of GSK5471713 in adult participants with metastatic castration resistant prostate cancer (mCRPC).
2025-523874-17-00Neoplasms, Prostate
Glaxosmithkline Research & Development Limited
Neoplasms
Netherlands, France, Spain
21/07/2026
Phase II
A Phase 2, open-label, randomized, dose optimization study evaluating the efficacy and safety of belantamab mafodotin administered in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed amyloid light chain amyloidosis (ALANIS)
2025-522803-60-00newly diagnosed amyloid light chain amyloidosis
Glaxosmithkline Research & Development Limited
Immune System Diseases
Italy, Greece, Spain
21/07/2026
Phase III
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens
2025-524336-19-00HIV-1
Gilead Sciences Inc.
Virus Diseases
Poland, Italy, France, Spain, Germany, Netherlands
21/07/2026
Phase III
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
2025-524335-39-00HIV-1
Gilead Sciences Inc.
Virus Diseases
Netherlands, Poland, Germany, France, Spain, Italy
21/07/2026
Phase III
A Phase 3, Double-blinded, Vehicle-controlled Trial to Investigate the Efficacy and Safety of Twice-daily Delgocitinib Cream in Adult Participants with Lichen Sclerosus During a 12-Week Initial Treatment Period Followed by a 40-Week Continuation Treatment Period
2025-524873-17-00Lichen Sclerosus
Leo Pharma A/S
Skin and Connective Tissue Diseases
Italy, France, Spain, Poland, Germany
21/07/2026
Phase I
Study of MX006 in Patients With Advanced and/or Metastatic Tumors known to express B7-H3
2025-524929-41-00Advanced Solid Tumor Types Known to Express B7-H3
Myricx Pharma Limited
Neoplasms
Spain
20/07/2026
Phase II
A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
2025-523908-75-00Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
AstraZeneca AB
Cardiovascular Diseases
Germany, Italy, Spain, France, Sweden
20/07/2026
Phase III
A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease
2025-522227-99-00Huntington’s Disease
Novartis Pharma AG
Nervous System Diseases
Norway, Poland, Spain, Sweden, Bulgaria, Netherlands, Finland, Portugal, Austria, Italy, Greece, Ireland, Czechia, France, Romania, Belgium, Germany, Denmark, Slovakia, Hungary
20/07/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
2025-524711-36-00Narcolepsy Type 1
Alkermes Inc.
Nervous System Diseases
Sweden, Finland, Belgium, Spain, Austria, Netherlands, France, Norway, Germany, Italy, Poland
20/07/2026
Phase III
Intrathecal Administration of MELPIDA For Hereditary Spastic Paraplegia Type 50 (SPG50): A multicenter Phase 3, Open-Label Trial with Matched Prospective Concurrent Control Arm (CT-MEL-03)
2025-524576-28-00Hereditary Spastic Paraplegia Type 50 (SPG50)
Elpida Therapeutics SPC
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain
17/07/2026
Phase II
An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension due to Interstitial Lung Disease
2026-525810-80-00Pulmonary hypertension secondary to interstitial lung disea…
Tectonic Operating Company Inc.
Cardiovascular Diseases
Poland, Romania, Spain
17/07/2026
Phase I
Bioequivalence clinical trial of two formulations of dapagliflozin/metformin
2026-527164-32-00Healthy participants
Laboratorios Alter S.A.
Nutritional and Metabolic Diseases
Spain
17/07/2026
Phase I/II
Phase I/II clinical trial on the use of central nervous system administrations of CART-NKG2D or NKIL15 cells in children, adolescent and young adults with recurrent/refractory high grade Central Nervous System tumours (CINK-CAR)
2026-525876-24-00Central nervous system tumours
Hospital Universitario La Paz
Neoplasms
Spain
15/07/2026
Phase III
The MODIFY Study: A Phase 3b/4 randomized, double-blind, placebo-controlled, multicentre study evaluating the impact of early intervention with depemokimab on exacerbation rate, clinical remission, lung function decline, and safety in adults and adolescents with at risk Type 2 asthma, conducted up to 156 weeks.
2025-524463-20-00Asthma
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Ireland, Spain, Germany, Czechia, Bulgaria, France, Belgium, Romania, Italy
14/07/2026
Phase III
A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan with or Without Bevacizumab Compared to Trifluridine/Tipiracil plus Bevacizumab in Participants with Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
2025-524648-37-00Metastatic colorectal cancer
Merck Healthcare KGaA
Neoplasms
Belgium, Germany, France, Denmark, Poland, Spain, Netherlands, Italy, Austria
14/07/2026
Phase III
A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis
2025-524448-36-00Focal segmental glomerulosclerosis (FSGS)
Apellis Pharmaceuticals Inc.
Female Urogenital Diseases and Pregnancy Complications
France, Portugal, Spain, Slovakia, Italy, Germany, Poland
14/07/2026
Phase III
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma
2025-525088-34-00Metastatic Pancreatic Adenocarcinoma
Revolution Medicines Inc.
Digestive System Diseases
Poland, Belgium, Norway, Sweden, Austria, Germany, Denmark, Netherlands, France, Italy, Spain
14/07/2026
Phase II
A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults with Antibody-mediated Kidney Disease
2025-524139-38-00Antibody-mediated Kidney Disease
AstraZeneca AB
Immune System Diseases
France, Germany, Italy, Belgium, Poland, Spain
13/07/2026
Phase II
A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of REC-4881 in Patients with Familial Adenomatous Polyposis (FAP)
2026-525282-50-00Familial Adenomatous Polyposis
Recursion Pharmaceuticals Inc.
Neoplasms
Netherlands, Germany, Spain
13/07/2026
Phase IV
Phase IV randomized, single-blind clinical trial with three parallel arms to compare ovulation triggering strategies in IVF cycles with fresh embryo transfer.
2026-526292-37-01Women with infertility and low ovarian reserve.
Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA
Reproductive and Urinary Physiological Phenomena
Spain
13/07/2026
Phase I
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
2026-525234-39-00Relapsed or Refractory acute myeloid leukemia, Relapsed or …
Janssen Cilag International
Neoplasms
France, Spain, Germany, Denmark, Belgium
13/07/2026
Phase II
Achieving viral CLEARance in immunocompromised participants with long-term persistence of SARS-CoV-2 - an open-label randomized trial (CLEAR)
2025-524442-10-00Long-term persistence of SARS-CoV-2
Goethe University Frankfurt
Virus Diseases
Germany, Spain
13/07/2026
Phase III
Effect of Vitamin D supplementation on MyocardIal Fibrosis in PaTients with Acute Myocarditis (EDIT-AM): a multicenter, open-label, randomized controlled trial
2025-523092-33-00Myocardial fibrosis, Acute myocarditis
Spanish Society Of Cardiology
Cardiovascular Diseases
Spain
10/07/2026
Phase II
A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement
2025-523923-22-00Previously Treated, Unresectable, Locally Advanced or Metas…
Elevar Therapeutics Inc.
Neoplasms
France, Spain
09/07/2026
Phase II
Master Protocol Full Title- A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 2 to Master Protocol ARGX-999-2-MG-2000 – an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
2025-522939-33-00AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthe…
Argenx
Immune System Diseases
Greece, Italy, Germany, Belgium, Netherlands, Spain, Poland
08/07/2026
Phase III
A multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy (Beltavac®) with Polymerized Allergenic Extract of a Mixture of Dermatophagoides and Blomia tropicalis in Patients with Allergic Rhinitis/rhinoconjunctivitis.
2026-526105-15-00Allergic rhinitis/rhinoconjunctivitis due to house dust mit…
Probelte Pharma S.L.
Eye Diseases
Spain
08/07/2026
Phase III
Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)
2023-505575-69-01Osteosarcoma
Institut Gustave Roussy
Neoplasms
Sweden, Poland, Denmark, Finland, Netherlands, Italy, France, Spain
08/07/2026
Phase II
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of E2086 in Adults with Narcolepsy
2025-523503-30-00Narcolepsy
Eisai Limited
Nervous System Diseases
Belgium, Italy, Spain, Germany
08/07/2026
Phase II
A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion
2025-524285-18-00Advanced and/or Metastatic Solid Tumors with Homozygous MTA…
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Belgium, Ireland, Germany, Norway, Italy, France, Spain
07/07/2026
Phase III
Multicenter, randomized, double-blind, parallel-group clinical study comparing RD03/2016 (levoFloxacin and ketorolac trometAmol) eye drops vs Leviosa® (levofloxacin and dexamethaSone 21-phosphaTe) eye drops for 7 days for the prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults. (FAST 7)
2026-525594-39-00Cataract
Ntc S.r.l.
Eye Diseases
Spain, Poland, Greece, Sweden, Italy
07/07/2026
Phase III
C6461016 - A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
2025-524717-86-00LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JU…
Pfizer Inc.
Neoplasms
France, Spain, Italy
07/07/2026
Phase III
A study to evaluate the dose-exposure, safety, and exploratory efficacy of nerandomilast in children and adolescents from 2 years to less than 18 years of age with fibrosing interstitial lung disease (Part A: double-blind, placebo-controlled in children from 6 to less than 18 years of age and open-label active treatment in children from 2 to less than 6 years of age), followed by an open-label phase with active treatment (Part B)
2025-523369-32-00Fibrosing interstitial lung disease
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Respiratory Tract Diseases
Belgium, Greece, Germany, France, Finland, Spain, Czechia, Poland, Italy, Netherlands, Denmark, Portugal
07/07/2026
Phase III
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Multiple Myeloma who Have Received One to Three Prior Lines of Therapy
2025-524028-23-00Multiple Myeloma
F. Hoffmann-La Roche AG
Neoplasms
France, Germany, Italy, Greece, Denmark, Czechia, Spain, Poland
07/07/2026
Phase III
Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288
2025-522563-15-00Metastatic Pancreatic Ductal Adenocarcinoma; PDAC
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Portugal, Spain, France, Italy, Germany, Austria
06/07/2026
Phase I
A study to investigate the repeat-dose pharmacokinetics of a combined oral contraceptive when given alone and in combination with ganfeborole in female participants of non-childbearing potential.
2026-525790-39-00Tuberculosis
Glaxosmithkline Research & Development Limited
Bacterial Infections and Mycoses
Spain
06/07/2026
Phase III
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype
2024-518016-39-00Respiratory tract diseases
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Denmark, Sweden, Poland, Estonia, Portugal, Latvia, Spain, Hungary, Germany, Finland, Italy, Belgium, France
06/07/2026
Phase III
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype
2024-518213-25-00Respiratory tract diseases
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Germany, Romania, Greece, Norway, Netherlands, Poland, Lithuania, Czechia, Slovakia, Spain
06/07/2026
Phase III
AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial)
2025-521929-32-01First Episode Psychosis (FEP)
University Of Oxford
Mental Disorders
Netherlands, Greece, Germany, Italy, Austria, Spain
01/07/2026
Phase I/II
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer
2025-523438-24-00DLL3 Expressing Tumors Including Small Cell Lung Cancer
Ideaya Biosciences Inc.
Neoplasms
France, Spain
01/07/2026
Phase III
"A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide"
2025-523815-12-00Relapsed or Refractory Multiple Myeloma
Janssen Cilag International
Neoplasms
Poland, Spain, Czechia, France, Italy, Germany, Greece
01/07/2026
Phase I
A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis
2025-523127-21-00Rheumatoid Arthritis
AbbVie Deutschland GmbH & Co. KG
Immune System Diseases
Belgium, Netherlands, Spain, Germany, Italy
01/07/2026
Phase III
A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)
2025-522167-15-00Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)
Genmab A/S
Neoplasms
Finland, Belgium, Hungary, France, Denmark, Austria, Germany, Italy, Spain, Czechia, Norway, Poland
01/07/2026
Phase I/II
A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs
2025-522723-98-00solid tumor
Krystal Biotech Inc.
Neoplasms
France, Spain
30/06/2026
Phase II
A phase IIa, single-arm, single-center, open label, proof-of-concept trial evaluating increased frequency dosing of VCN-01 (zabilugene almadenorepvec) in combination with nab-Paclitaxel/Gemcitabine (GnP) in Patients with Newly-Diagnosed Metastatic Pancreatic Cancer (VIRAGE2)
2026-525566-21-00metastatic pancreatic adecarcinoma
Theriva Biologics S.L.
Neoplasms
Spain
30/06/2026
Phase III
A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection
2025-521971-29-00Non Small Cell Lung Cancer (NSCLC)
Nuvation Bio Inc.
Respiratory Tract Diseases
Spain, Belgium, France, Italy, Germany
30/06/2026
Phase III
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
2025-521769-29-00Pulmonary Hypertension Associated with Interstitial Lung Di…
Insmed Inc.
Respiratory Tract Diseases
Greece, France, Italy, Belgium, Denmark, Germany, Poland, Czechia, Portugal, Austria, Spain, Romania
30/06/2026
Phase I/II
Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients with Dravet Syndrome
2025-523835-20-00Dravet Syndrome
Ionis Pharmaceuticals Inc.
Nervous System Diseases
Spain, France, Belgium, Portugal, Germany
30/06/2026
Phase III
A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma
2025-524397-42-00Participants with relapsed HRNB and participants with HRNB…
Renaissance Pharma Limited
Nervous System Diseases
France, Spain, Denmark, Ireland, Germany
30/06/2026
Phase I
A Phase 1 Randomized, Double-Blind, placebo-controlled, clinical study to evaluate safety and Pharmacokinetics, of Single Ascending Doses and Multiple Ascending Doses of AIK3a305 in Healthy Volunteers
2026-525830-49-00Treatment of several inflammatory diseases, including infla…
Allinky Biopharma S.L.
Not possible to specify
Spain
29/06/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
2025-524855-30-00Cutaneous Manifestations of Lupus Erythematosus With or Wit…
Merck Healthcare KGaA
Skin and Connective Tissue Diseases
Germany, Romania, France, Bulgaria, Belgium, Spain, Poland, Greece, Italy, Czechia
29/06/2026
Rows per page Showing 101–200 of 1018
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-europe/country/spain?page=2

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.